This bill amends the Omnibus Crime Control and Safe Streets Act of 1968 by changing the statutory authorization language for the Department of Justice’s Comprehensive Opioid Abuse Grant Program. Concretely, it removes a clause that references $103,000,000 for fiscal years 2017 and 2018 and replaces the phrase “2019 through 2023” with “2026 through 2030.”
On its face, the measure is a narrow reauthorization: it updates the statutory window for the program so the authority to operate is extended into the late 2020s. That matters to DOJ grant administrators, state and local grantees, and treatment and diversion program operators because it preserves the program’s statutory existence while leaving questions about exact funding levels and a possible authorization gap for 2024–2025 unresolved.
At a Glance
What It Does
The bill amends 34 U.S.C. 10261(a)(27) by striking the clause that specifies "$103,000,000 for each of fiscal years 2017 and 2018, and" and by replacing the statutory range "2019 through 2023" with "2026 through 2030." It therefore reauthorizes the Comprehensive Opioid Abuse Grant Program for 2026–2030.
Who It Affects
Directly affected parties include DOJ’s grant-making offices, state and local criminal justice agencies that apply for these grants, treatment providers and recovery courts that receive funding, and congressional appropriations committees that set actual dollar levels.
Why It Matters
Reauthorization keeps the program on the statute books through 2030, enabling DOJ to continue grant activity subject to appropriations. But the amendment leaves funding amounts for the new authorization window unspecified and creates a two‑year gap (2024–2025) between the old and new statutory ranges unless Congress takes additional action.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill is short and surgical. It gives the Comprehensive Opioid Abuse Grant Program a new statutory life span by changing two bits of statutory text: it removes an explicit reference to $103,000,000 tied to fiscal years 2017 and 2018, and it shifts the multi‑year authorization window from “2019 through 2023” to “2026 through 2030.” There is no other policy text, program redesign, or new eligibility language in the draft; it does not itself appropriate money or create new grant requirements.
For practitioners, the immediate practical result is that the program will be authorized in statute for another five fiscal years, which is the precondition for DOJ to plan multi‑year competitions and for applicants to expect a continuing grant program. But authorization language and appropriations are distinct: the bill does not set dollar amounts for 2026–2030, so actual funding will require action by the Appropriations Committees.A consequential drafting effect is timing.
The current statutory language covered through 2023; this bill covers 2026–2030. Unless Congress or the President acts elsewhere, the statute would not explicitly authorize the program for fiscal years 2024 or 2025.
That creates a potential two‑year authorization gap that could complicate DOJ’s grant planning and multi‑year awards and may force stop‑gap appropriations or other legislative fixes.Finally, because the bill deletes the 2017–2018 dollar clause rather than reprinting dollar amounts for the new window, it leaves open interpretive questions about whether past funding language carried formulas or ceilings that drafters intended for later years. Practically, agencies and grantees should treat this as a statutory housekeeping/reauthorization measure that preserves the program but does not guarantee specific funding levels or timing.
The Five Things You Need to Know
The bill amends 34 U.S.C. 10261(a)(27), the statutory provision authorizing the Comprehensive Opioid Abuse Grant Program.
It strikes the text: "$103,000,000 for each of fiscal years 2017 and 2018, and", removing that explicit past-fiscal-year dollar reference from the statute.
It replaces the phrase "2019 through 2023" with "2026 through 2030," extending the program’s statutory authorization window by five years.
The text does not appropriate funds or specify dollar amounts for the 2026–2030 authorization period; funding still requires annual appropriation by Congress.
Because the amendment moves the covered period from ending in 2023 to starting in 2026, the statute would not explicitly authorize the program for FY2024–FY2025 unless Congress acts elsewhere.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Provides the Act’s short title: the "Comprehensive Addiction and Recovery Justice Grant Reauthorization Act." This is a standard heading with no operational effect, but the short title frames the bill as a reauthorization (not a substantive program change), which matters for how agencies and stakeholders read the intent behind the amendment.
Amendment to 34 U.S.C. 10261(a)(27)
Directs a two‑part edit to the statutory paragraph that authorizes the Comprehensive Opioid Abuse Grant Program: first it removes a clause that specified a $103 million figure for FY2017–FY2018; second it substitutes the original multi‑year authorization window ending in 2023 with a new window covering 2026–2030. Mechanically, this keeps the statutory grant authority alive beyond 2025 but does not itself set appropriation levels, modify eligible activities, or change administrative rules for grant competitions.
Practical consequences for funding and timing
The bill contains no separate section on effective dates or transitional rules, so the amendment would take effect on enactment. That means DOJ would have revised statutory authority but must still rely on regular appropriations to fund awards. The absence of language covering FY2024–FY2025 means agencies, grantees, and appropriators will need to coordinate to avoid interruptions in multi‑year grants or to pass short‑term authorizations or appropriations if Congress wants to preserve continuity.
This bill is one of many.
Codify tracks hundreds of bills on Justice across all five countries.
Explore Justice in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Current and prospective DOJ grantees (state/local justice agencies, treatment providers, recovery courts): the reauthorization keeps the program on the statute books, allowing DOJ to plan future solicitations and giving applicants a plausible expectation that the program will exist into 2030.
- Community-based treatment and diversion programs that rely on federal grant cycles: maintaining statutory authority reduces the risk that the program will be discontinued entirely and preserves an avenue for federal support.
- Policy advocates and researchers focused on opioid response: a multi‑year authorization supports longer-term program evaluation and continuity for evidence-building initiatives.
- DOJ grant administrators: statutory reauthorization simplifies program continuity from a legal-authority perspective, avoiding the need for ad hoc legislative creations to continue the program’s existence.
Who Bears the Cost
- Congressional appropriations committees and ultimately taxpayers: actual outlays for any awards in 2026–2030 require new appropriations decisions and fiscal trade-offs with other funding priorities.
- DOJ (Office of Justice Programs and grant offices): administering multi‑year competitions and resolving timing ambiguity for awards will create administrative burdens and require guidance to grantees.
- Grantees with multi‑year awards that overlap the unauthorized gap (if no interim fix is passed): they face uncertainty about mid‑grant funding continuity and potential interruptions to services.
- Smaller nonprofits and service providers: if appropriations are constrained, competition for fewer dollars could increase, disproportionately affecting smaller organizations with less capacity to pursue federal grants.
Key Issues
The Core Tension
The central dilemma is between legal continuity and fiscal control: Congress can extend a program’s statutory authorization to provide confidence and permit planning, but doing so without specifying appropriations or addressing the interim years hands responsibility back to appropriators and agencies — creating the risk of a guidance‑driven continuity that lacks guaranteed funding and leaves grantees exposed to timing gaps.
The bill is narrowly focused on statutory dates and the deletion of an earlier dollar clause; that surgical approach creates several practical tensions. First, reauthorization without specifying dollar amounts leaves a common but important separation of powers: Congress authorizes programs but retains appropriations control.
Grantees often treat an authorization extension as a signal of likely funding, but the statute alone does not create an appropriation — and absent sufficient appropriations, the program could be authorized but unfunded.
Second, the amendment creates an interpretive and operational timing problem. By ending the prior statutory window in 2023 and restarting authorization in 2026, the text leaves FY2024–FY2025 without explicit statutory coverage.
That gap is likely a drafting consequence rather than policy intent, but it matters: DOJ’s grant cycles and existing multi‑year awards often straddle fiscal years, and a statutory gap could complicate obligations, audit positions, or OMB/GAO determinations unless Congress clarifies the interim period or funds grants through appropriations law.
Third, removing the explicit $103,000,000 reference for FY2017–FY2018 is a cleanup that may have downstream implications for stakeholders searching the statute for historic funding levels or formulas. If any program rules or internal agency regulations referenced that past statutory language, agencies will need to confirm that the deletion has no unintended operational effect.
In short, the measure preserves the program’s statutory life but leaves funding, timing, and interpretive questions for appropriators and agency counsel to resolve.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.